Recombinant Rhesus Macaque CDK9 Protein Pre-coupled Magnetic Beads

• Cat.No.: CDK9-617R-B
• Product Overview: The Recombnant protein was conjugated to magnetic beads. This ready-to-use, pre-coupled magnetic beads are in uniform particle size and narrow size distribution with large surface area, which is conducive to convenient and fast capture target molecules with high specificity and achieve magnetic separation. This product can be equipped with automation equipment for high-throughput operations.

Specification

• Source: HEK293
• Species: Rhesus Macaque
• Form: Solution
• Particle size: ~2 μm
• Beads Surface: Hydrophilic
• Capacity: > 200 pmol rabbit IgG/ mg beads
• Applications: Immunoassay, In vitro diagnostics, cell sorting, Immunoprecipitation/Co-precipitation, Protein/antibody separation and purification.
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions.
• Storage: 2-8℃. Do not to freeze thaw the Beads
• Concentration: 10mg beads/mL
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: CDK9 cyclin-dependent kinase 9 [ Macaca mulatta (Rhesus monkey) ]
• Official Symbol: CDK9
• Synonyms: CDK9; cyclin-dependent kinase 9
• Gene ID: 699840
• mRNA Refseq: NM_001266230
• Protein Refseq: NP_001253159
• UniProt ID: H9FNK6

Reviews

08/31/2020

Its remarkable quality, versatility, and the manufacturer's commitment to customer satisfaction make it the perfect choice for researchers seeking a premier protein that will undoubtedly enhance their experimental endeavors.

06/26/2019

In addition to its remarkable quality and exceptional technical support, the CDK9 Protein boasts an impressive range of applications.

09/12/2018

The CDK9 Protein has exceeded my expectations by consistently delivering outstanding results and providing exceptional technical support.

Q&As

Is CDK9 targeted only for cancer and antiviral therapies, or are there other applications?

Besides cancer and antiviral therapies, CDK9 is being explored for its role in other diseases, including neurodegenerative disorders.

Can CDK9 inhibitors be used in combination with other cancer treatments?

Yes, combination therapies involving CDK9 inhibitors and other drugs are being investigated to enhance treatment outcomes.

How does the expression of CDK9 vary in different stages of cancer progression?

CDK9 expression tends to increase as cancer progresses, suggesting its potential as a biomarker for disease severity.

How does CDK9 inhibition affect normal cellular functions?

CDK9 inhibitors can impact normal cell functions, leading to potential side effects such as myelosuppression.

Are there ongoing clinical trials involving CDK9 inhibitors?

Yes, several clinical trials are exploring the effectiveness of CDK9 inhibitors in different cancer types.